MX2007003471A - Nueva forma cristalina de clorhidrato de (3-cian-1h-indol-7-il)-[4 -(4-fluorofenetil)-piperazin-1-il]-metanona. - Google Patents

Nueva forma cristalina de clorhidrato de (3-cian-1h-indol-7-il)-[4 -(4-fluorofenetil)-piperazin-1-il]-metanona.

Info

Publication number
MX2007003471A
MX2007003471A MX2007003471A MX2007003471A MX2007003471A MX 2007003471 A MX2007003471 A MX 2007003471A MX 2007003471 A MX2007003471 A MX 2007003471A MX 2007003471 A MX2007003471 A MX 2007003471A MX 2007003471 A MX2007003471 A MX 2007003471A
Authority
MX
Mexico
Prior art keywords
indol
piperazine
cyano
crystalline form
fluorophenethyl
Prior art date
Application number
MX2007003471A
Other languages
English (en)
Spanish (es)
Inventor
Andreas Bathe
Bernd Helfert
Ralf Knierieme
Christoph Saal
Ronald Keiner
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2007003471A publication Critical patent/MX2007003471A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Anesthesiology (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
MX2007003471A 2004-09-28 2005-09-08 Nueva forma cristalina de clorhidrato de (3-cian-1h-indol-7-il)-[4 -(4-fluorofenetil)-piperazin-1-il]-metanona. MX2007003471A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE102004047517A DE102004047517A1 (de) 2004-09-28 2004-09-28 Neuartige Kristallform von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, Hydrochlorid
PCT/EP2005/009647 WO2006034774A1 (de) 2004-09-28 2005-09-08 Neuartige kristallform von (3-cyan-1h-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon, hydrochlorid

Publications (1)

Publication Number Publication Date
MX2007003471A true MX2007003471A (es) 2007-05-10

Family

ID=35285234

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2007003471A MX2007003471A (es) 2004-09-28 2005-09-08 Nueva forma cristalina de clorhidrato de (3-cian-1h-indol-7-il)-[4 -(4-fluorofenetil)-piperazin-1-il]-metanona.

Country Status (16)

Country Link
US (1) US7981897B2 (enExample)
EP (1) EP1794121B1 (enExample)
JP (1) JP5160892B2 (enExample)
KR (1) KR20070057872A (enExample)
CN (1) CN101027284B (enExample)
AR (1) AR051043A1 (enExample)
AU (1) AU2005289169B2 (enExample)
BR (1) BRPI0516200A (enExample)
CA (1) CA2581834A1 (enExample)
DE (1) DE102004047517A1 (enExample)
MX (1) MX2007003471A (enExample)
PE (1) PE20060964A1 (enExample)
RU (1) RU2383532C2 (enExample)
TW (1) TW200616952A (enExample)
WO (1) WO2006034774A1 (enExample)
ZA (1) ZA200703440B (enExample)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101437793B (zh) * 2006-05-05 2012-08-22 默克专利股份有限公司 结晶的（3-氰基-1h-吲哚-7-基）-[4-（4-氟苯乙基）哌嗪-1-基]甲酮磷酸盐
CA2652215A1 (en) * 2006-05-05 2007-11-15 Merck Patent Gesellschaft Mit Beschraenkter Haftung Crystalline (3-cyano-1h-indol-7-yl)-[4-(4-fluorophenethyl)piperazin-1-yl]methanone phosphate
MY148643A (en) * 2007-05-11 2013-05-15 Richter Gedeon Nyrt Solvate and crystalline forms of carbamoyl-cyclohexane derivatives
HUP0700353A2 (en) * 2007-05-18 2008-12-29 Richter Gedeon Nyrt Metabolites of (thio)carbamoyl-cyclohexane derivatives
US7875610B2 (en) * 2007-12-03 2011-01-25 Richter Gedeon Nyrt. Pyrimidinyl-piperazines useful as D3/D2 receptor ligands
CA2715760C (en) * 2008-02-21 2017-06-13 Mitsubishi Tanabe Pharma Corporation Solid preparation for oral administration of cariprazine hydrochloride
AU2009270823B2 (en) 2008-07-16 2014-07-17 Richter Gedeon Nyrt. Pharmaceutical formulations containing dopamine receptor ligands
HU230067B1 (hu) 2008-12-17 2015-06-29 Richter Gedeon Nyrt Új piperazin só és eljárás előállítására
HUP0800766A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Vegyeszet Process for the preparation of piperazine derivatives
HUP0800765A2 (en) 2008-12-18 2010-11-29 Richter Gedeon Nyrt A new process for the preparation of piperazine derivatives and their hydrochloric salts
US8912197B2 (en) 2012-08-20 2014-12-16 Forest Laboratories Holdings Ltd. Crystalline form of carbamoyl-cyclohexane derivatives
US11274087B2 (en) 2016-07-08 2022-03-15 Richter Gedeon Nyrt. Industrial process for the preparation of cariprazine
US11547707B2 (en) 2019-04-10 2023-01-10 Richter Gedeon Nyrt. Carbamoyl cyclohexane derivatives for treating autism spectrum disorder

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2084531A1 (en) * 1991-12-19 1993-06-20 David W. Smith Antimigraine 4-pyrimidinyl and pyridinyl derivatives of indol-3yl-alkyl piperazines
DE19934433A1 (de) * 1999-07-22 2001-01-25 Merck Patent Gmbh N-(Indolcarbonyl-)piperazinderivate
DE10102944A1 (de) * 2001-01-23 2002-07-25 Merck Patent Gmbh Verfahren zur Herstellung von (3-Cyan-1H-indol-7-yl)-[4-(4-fluorphenethyl)-piperazin-1-yl]-methanon und dessen Salzen
DE10157673A1 (de) * 2001-11-24 2003-06-05 Merck Patent Gmbh Verwendung von N-(Indolcarbonyl-)piperazinderivaten
DE10246357A1 (de) * 2002-10-04 2004-04-15 Merck Patent Gmbh Verwendung von 5-HT2Rezeptorantagonisten

Also Published As

Publication number Publication date
EP1794121B1 (de) 2013-12-25
CA2581834A1 (en) 2006-04-06
EP1794121A1 (de) 2007-06-13
CN101027284B (zh) 2010-09-29
WO2006034774A1 (de) 2006-04-06
RU2383532C2 (ru) 2010-03-10
US20070259885A1 (en) 2007-11-08
RU2007116037A (ru) 2008-11-10
BRPI0516200A (pt) 2008-08-26
AU2005289169B2 (en) 2011-07-14
TW200616952A (en) 2006-06-01
CN101027284A (zh) 2007-08-29
KR20070057872A (ko) 2007-06-07
JP2008514558A (ja) 2008-05-08
AU2005289169A1 (en) 2006-04-06
US7981897B2 (en) 2011-07-19
DE102004047517A1 (de) 2006-03-30
ZA200703440B (en) 2008-08-27
AR051043A1 (es) 2006-12-13
PE20060964A1 (es) 2006-10-02
JP5160892B2 (ja) 2013-03-13

Similar Documents

Publication Publication Date Title
PT1940839E (pt) Inibidores de piridopirimidinona pi3k alfa
WO2010123919A3 (en) Piperidine inhibitors of janus kinase 3
WO2007015017A3 (fr) Nouveaux derives de polyquinoleines et leur utilisation therapeutique
TW200604184A (en) Processes and intermediates useful for preparing fused heterocyclic kinase inhibitors
WO2005108358A3 (en) Pyrrolidine derivatives useful as bace inhibitors
MX2009014208A (es) Compuestos heterociclicos y usos de los mismos como inhibidores de erk.
PL1802573T3 (pl) Proces syntezy 4-(3-metanosulfonylofenylo)-1-N-propylopiperydyny
IL183526A0 (en) 4-(4-(imidazol-4-yl)pyrimidin-2-ylamino)benzamides as cdk inhibitors
TW200732324A (en) Novel compounds that are ERK inhibitors
TW200745089A (en) Novel compounds that are ERK inhibitors
IL183237A0 (en) Polymorphs of memantine hydrochloride
MX2009003763A (es) Inhibidores de metaloproteasa derivados de heterociclicos.
TW200635913A (en) Process for preparing pharmaceutically acceptable salts of duloxetine and intermediates thereof
WO2006034093A3 (en) 3- (2-acylamino-1-hydroxyethyl)- morpholine derivatives and their use as bace inhibitors
ZA200703440B (en) Novel crystalline form of (3-cyano-1H-indol-7-yl)-[4-(4-fluorophenthyl)-piperazine-1-yl]-methanone hydrochloride
NO20071254L (no) Fremgangsmate for fremstilling av irbesartan og mellomprodukter derav.
MY151229A (en) Crystalline form of a 4-[2-(2-fluorophenoxymethyl)phenyl]piperidine compound
NO20080033L (no) Kinolinderivater som NK3-antagonister
MXPA05013758A (es) Composiciones farmaceuticas que incluyen una antihistamina y un estimulante y uso de las mismas.
PL1758852T3 (pl) Podstawione związki cyklopentenu
IL172542A0 (en) 2-hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide
ATE466842T1 (de) 3-substituierte pyridinderivate als h3- antagonisten
WO2006081515A3 (en) Duloxetine hydrochloride polymorphs
TW200640886A (en) Crystalline forms of linezolid intermediate
PL1888514T3 (pl) Sole podstawionych estrów kwasu alofanowego i ich zastosowanie w środkach leczniczych

Legal Events

Date Code Title Description
FA Abandonment or withdrawal